1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
SK Discovery Co. Ltd.

SK Discovery Co. Ltd.

40,050.00
KRW
-350.00
(-0.87%)
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
8,256,550
7,283,608
5,269,176
5,322,182
6,415,901
6,939,172
5,021,068
4,519,464
6,614,328
8,717,115
8,939,217
9,039,603
10,164,014
11,604,940
Operating Margin (%)
2.35
2.05
2.28
3.56
1.28
1.44
3.46
3.83
1.12
4.16
2.87
1.91
3.56
2.78
Depreciation Expense
79,500
85,154
103,074
110,910
127,617
59,589
106,742
114,428
116,090
180,515
346,288
367,750
522,213
556,695
Net Income, GAAP
-30,900
-25,089
55,551
82,617
717,913
70,761
180,383
267,001
212,899
427,432
191,035
36,471
129,347
187,611
Effective Tax Rate (%)
76.14
59.23
19.32
27.76
24.74
63.17
- -
31.13
25.35
0.93
29.4
32.71
23.89
39.15
Profit Margin (%)
-0.37
-0.34
1.05
1.55
11.19
1.02
3.59
5.91
3.22
4.9
2.14
0.4
1.27
1.62
Working Capital
583,590
518,067
986,459
374,379
624,590
75,236
330,192
1,002,127
824,166
2,043,155
2,182,404
1,699,650
1,722,337
2,945,215
LT Debt
1,245,017
1,794,543
2,402,497
1,324,631
1,076,266
505,758
895,085
1,387,902
1,588,274
2,047,384
2,873,198
4,113,337
4,988,660
5,160,540
Total Equity
1,783,544
2,006,100
2,585,779
2,662,430
2,143,595
2,318,569
2,323,215
2,616,362
3,069,308
5,953,322
6,069,572
6,503,023
6,851,246
8,229,630
Return on Invested Capital (%)
1.19
1.4
1.82
2.43
1.28
0.91
- -
2.61
0.99
4.36
1.72
0.97
2.02
1.29
Return on Capital (%)
-1.42
-0.9
1.43
0.39
13.83
1.52
- -
4.68
3.48
5.03
2.33
1.18
2.19
2.23
Return on Common Equity (%)
-2.44
-2.03
4.12
5.4
53.94
5.59
11.57
14.77
9.8
16.38
6.65
1.26
4.5
5.88

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,307,542
2,726,481
3,112,799
LT Borrowings
3,873,079
4,184,839
4,008,869
LT Finance Leases
1,115,581
1,089,505
1,151,670
Preferred Equity and Hybrid Capital
6,792
6,792
6,792
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,465,970
6,822,257
8,156,161
Cash, Cash Equivalents & STI
2,463,603
2,888,282
4,358,243
Accounts Receivable, Net
1,203,956
1,473,087
1,440,606
Inventories
1,302,337
1,270,593
1,412,318
Total Current Liabilities
3,743,633
4,683,210
5,210,946
Payables & Accruals
- -
- -
- -
ST Debt
2,307,542
2,726,481
3,112,799
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.02%
25.14%
5.35%
Free Cash Flow
-123.6%
-209.88%
-74.63%
Net Income, GAAP
112.94%
39.79%
254.66%
Sales/Revenue/Turnover
8.63%
18.85%
12.44%
Total Cash Common Dividend
20.15%
22.98%
7.26%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,158,527
2,119,448
2,189,579
2,572,049
9,039,603
2025
2,406,122
2,497,785
2,601,280
2,658,828
10,164,014
2026
3,289,250
3,055,582
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chang-Won Chey
Full Time Employees
65
Sector
Health technology
Industry
Pharmaceuticals: major
Address
ECO Hub Seongnam-si GY South Korea 13493
IPO Date
Jun 29, 1976
Website
skdiscovery.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SK Discovery Co., Ltd. is a South Korea-based holding company primarily engaged in the management and support of its subsidiaries operating in the environmental-friendly materials, pharmaceuticals, and energy sectors. Founded as a holding entity with headquarters in Seoul, SK Discovery oversees SK Chemicals, SK Gas, SK Bioscience, and SK Plasma among others, facilitating strategic growth and portfolio expansion. Its core businesses include the manufacture and sale of green chemicals such as copolyesters, coatings, adhesives, electronic chemicals, engineering plastics, prepregs, and biomaterials; pharmaceutical products spanning prescription medicines, OTC drugs, vaccines, and healthcare IT solutions integrating nanotechnology and biotechnology; energy-related operations involving LPG storage, tank terminals, and power generation; and bio-pharmaceuticals with vaccine development and plasma-derived medicines. Recent significant developments include SK Discovery's strategic divestment of its entire stake in its real estate affiliate SK D&D in a deal valued at approximately 74.2 billion won in 2025, refocusing the company on its core competencies of green materials, biotechnology, and energy. Additionally, SK Biopharmaceuticals, a key subsidiary, launched a new AI digital health joint venture, Mentis Care, in partnership with Brazil’s Eurofarma, aimed at advancing AI-driven epilepsy management solutions through predictive seizure technology, marking an expansion into digital healthcare. SK Discovery also completed an additional acquisition of a 5.22% stake in SK Chemicals in 2022, reinforcing its controlling interest. The company emphasizes ESG commitments, promoting recycled plastic businesses and hydrogen value chains to enhance sustainability. Geographically, SK Discovery operates broadly in South Korea and across international markets through its subsidiaries, targeting markets demanding advanced chemicals, pharmaceutical products, and sustainable energy solutions. This integrated portfolio and strategic reorientation position SK Discovery as a leading player in chemical, pharmaceutical, and energy innovation within South Korea and globally. The company continuously pursues new growth avenues via partnerships, investments, and technology-driven healthcare solutions to drive long-term shareholder value and business resilience.